Currently available biomaterials for use in cardiopulmonary bypass

References

• Wangensteen OH, Wangensteen SD. The Rise of Surgery. University of Minnesota Press, MN, USA (1978).
   Google Scholar
• Walport MJ. Complement. First of two parts. N. Engl. J. Med.344(14), 1058–1066 (2001).
   PubMed Web of Science ®Google Scholar
• Walport MJ. Complement. Second of two parts. N. Engl. J. Med.344(15), 1140–1144 (2001).
   PubMed Web of Science ®Google Scholar
• Edmunds HL, Hessel EA, Colman RW, Menasche P. Extracorporeal circulation. In: Cardiac Surgery in the Adult. Edmunds HL, Cohn LH (Eds), McGraw-Hill Professional, NY, USA, 315–387 (2003).
   Google Scholar
• Edmunds LH Jr. Advances in the heart–lung machine after John and Mary Gibbon. Ann. Thorac. Surg.76(6), S2220–S2223 (2003).
   Google Scholar
• Rubens FD. Cardiopulmonary bypass: technique and pathophysiology. In: Sabiston & Spencer Surgery of the Chest. Selke FW, del Nido PJ, Swanson SJ (Eds), Elsevier Saunders, PA, USA, 1061–1080 (2005).
   Google Scholar
• Rubens FD. Cardiopulmonary bypass technology transfer: musings of a cardiac surgeon. J. Biomater. Sci. Polym. Ed.13(4), 485–499 (2002).
   PubMed Web of Science ®Google Scholar
• Tanzi MC. Bioactive technologies for hemocompatibility. Expert Rev. Med. Devices2(4), 473–492 (2005).
   PubMed Web of Science ®Google Scholar
• Campbell EJ, O’Byrne V, Stratford PW et al. Biocompatible surfaces using methacryloylphosphorylcholine laurylmethacrylate copolymer. ASAIO J.40(3), M853–M857 (1994).
   PubMedGoogle Scholar
• Mombouli JV, Vanhoutte PM. Endothelial dysfunction: from physiology to therapy. J. Mol. Cell. Cardiol.31(1), 61–74 (1999).
   PubMed Web of Science ®Google Scholar
• Rubens FD, Labow RS, Lavallee GR et al. Hematologic evaluation of cardiopulmonary bypass circuits prepared with a novel block copolymer. Ann. Thorac. Surg.67, 689–698 (1999).
   PubMedGoogle Scholar
• Kitaguchi H, Hijikata A, Hirata M. Effect of thrombin on plasminogen activator release from isolated perfused dog leg. Thromb. Res.16, 407–415 (1979).
   PubMedGoogle Scholar
• Coughlin SR, Vu TK, Hung DT, Wheaton VI. Characterization of a functional thrombin receptor. Issues and opportunities. J. Clin. Invest.89(2), 351–355 (1992).
   PubMed Web of Science ®Google Scholar
• Steinberg JB, Kapelanski DP, Olson JD, Weiler JM. Cytokine and complement levels in patients undergoing cardiopulmonary bypass. J. Thorac. Cardiovasc. Surg.106(6), 1008–1016 (1993).
   PubMed Web of Science ®Google Scholar
• Cavarocchi NC, Pluth JR, Schaff HV et al. Complement activation during cardiopulmonary bypass. Comparison of bubble and membrane oxygenators. J. Thorac. Cardiovasc. Surg.91(2), 252–258 (1986).
   PubMed Web of Science ®Google Scholar
• Wiggins RC, Giclas PC, Henson PM. Chemotactic activity generated from the fifth component of complement by plasma kallikrein of the rabbit. J. Exp. Med.153(6), 1391–1404 (1981).
   PubMedGoogle Scholar
• Ward PA. A plasmin-split fragment of C´3 as a new chemotactic factor. J. Exp. Med.126(2), 189–206 (1967).
   PubMed Web of Science ®Google Scholar
• Tengvall P, Askendal A, Lundstrom I. Temporal studies on the deposition of complement on human colostrum IgA and serum IgG immobilized on methylated silicon. J. Biomed. Mater. Res.35(1), 81–92 (1997).
   PubMed Web of Science ®Google Scholar
• Gorbet MB, Sefton MV. Biomaterial-associated thrombosis: roles of coagulation factors, complement, platelets and leukocytes. Biomaterials25, 5681–5703 (2004).
   PubMed Web of Science ®Google Scholar
• Gott VL. And it happened during our lifetime. Ann. Thorac. Surg.55(5), 1057–1064 (1993).
   PubMed Web of Science ®Google Scholar
• Voorhees ME, Brian BF. Blood–gas exchange devices. Int. Anesthesiol. Clin.34(2), 29–45 (1996).
   PubMedGoogle Scholar
• Rosen JJ. The role of biomaterials science in the next generation of artificial organ technology. ASAIO Trans.34(3), 163–167 (1988).
   Google Scholar
• Wendel HP, Ziemer G. Coating-techniques to improve the hemocompatibility of artificial devices used for extracorporeal circulation. Eur. J. Cardiothorac. Surg.16(3), 342–350 (1999).
   PubMed Web of Science ®Google Scholar
• Gott VL, Daggett RL. Serendipity and the development of heparin and carbon surfaces. Ann. Thorac. Surg.68, S19–S22 (1999).
   PubMed Web of Science ®Google Scholar
• Gott VL, Whiffen JD, Dutton RC. Heparin bonding on colloidal graphite surfaces. Science14, 1297–1298 (1963).
   Google Scholar
• Baier RE. The role of surface energy in thrombogenesis. Bull. N Y Acad. Med.48(2), 257–272 (1972).
   PubMedGoogle Scholar
• Lee JH, Lee HB. Platelet adhesion onto wettability gradient surfaces in the absence and presence of plasma proteins. J. Biomed. Mater. Res.41(2), 304–311 (1998).
   PubMed Web of Science ®Google Scholar
• Salzman EW. Nonthrombogenic surfaces: critical review. Blood38(4), 509–523 (1971).
   PubMed Web of Science ®Google Scholar
• Uniyal S, Brash JL. Patterns of adsorption of proteins from human plasma onto foreign surfaces. Thromb. Haemost.47, 285–295 (1982).
   PubMed Web of Science ®Google Scholar
• Horbett TA. Proteins; structure, properties, and adsorption to surfaces. In: Biomaterials Science. An Introduction to Materials in Medicine. Ratner BD, Hoffman AS, Schoen FJ, Lemon JE (Eds), Academic Press, CA, USA, 133–141 (1996).
   Google Scholar
• Brash JL, Scott CF, ten Hove P, Wojciechowski P, Colman RW. Mechanism of transient adsorption of fibrinogen from plasma to solid surfaces: role of the contact and fibrinolytic systems. Blood71, 932–939 (1988).
   PubMed Web of Science ®Google Scholar
• Lindon JN, McManama G, Kushner L, Merrill EW, Salzman EW. Does the conformation of adsorbed fibrinogen dictate platelet interactions with artificial surfaces? Blood68(2), 355–362 (1986).
   PubMed Web of Science ®Google Scholar
• Larm O, Larsson R, Olsson P. A new non-thrombogenic surface prepared by selective covalent binding of heparin via a modified reducing terminal residue. Biomater. Med. Devices Artif. Organs11(2–3), 161–173 (1983).
   PubMed Web of Science ®Google Scholar
• Johnell M, Elgue G, Larsson R, Larsson A, Thelin S, Siegbahn A. Coagulation, fibrinolysis, and cell activation in patients and shed mediastinal blood during coronary artery bypass grafting with a new heparin-coated surface. J. Thorac. Cardiovasc. Surg.124(2), 321–332 (2002).
   PubMed Web of Science ®Google Scholar
• Johnell M, Larsson R, Siegbahn A. The influence of different heparin surface concentrations and antithrombin-binding capacity on inflammation and coagulation. Biomaterials26(14), 1731–1739 (2005).
   PubMed Web of Science ®Google Scholar
• Feyrer R, Harig F, Cesnjevar R. Bioline or Safeline treatment of CPB circuits? Cardiovasc. Eng.8, 1–2 (2003).
   Google Scholar
• Tayama E, Hayashida N, Akasu K et al. Biocompatibility of heparin-coated extracorporeal bypass circuits: new heparin bonded bioline system. Artif. Organs24(8), 618–623 (2000).
   PubMed Web of Science ®Google Scholar
• Larson DF, Arzouman D, Kleinert L, Patula V, Williams S. Comparison of Sarns 3M heparin bonded to Duraflo II and control circuits in a porcine model: macro- and microanalysis of thrombi accumulation in circuit arterial filters. Perfusion15(1), 13–20 (2000).
   Google Scholar
• Rubens FD, Mesana T. The inflammatory response to cardiopulmonary bypass: a therapeutic overview. Perfusion19(Suppl. 1), S5–S12 (2004).
   PubMedGoogle Scholar
• Elgue G, Blomback M, Olsson P, Riesenfeld J. On the mechanism of coagulation inhibition on surfaces with end point immobilized heparin. Thromb. Haemost.70(2), 289–293 (1993).
   PubMed Web of Science ®Google Scholar
• Ovrum E, Holen EA, Tangen G et al. Completely heparinized cardiopulmonary bypass and reduced systemic heparin: clinical and hemostatic effects. Ann. Thorac. Surg.60(2), 365–371 (1995).
   PubMed Web of Science ®Google Scholar
• Aldea GS, Doursounian M, O’Gara P et al. Heparin-bonded circuits with a reduced anticoagulation protocol in primary CABG: a prospective, randomized study. Ann. Thorac. Surg.62, 410–418 (1996).
   PubMed Web of Science ®Google Scholar
• Brown C. Heparin-bonded circuits: clinical outcomes and costs. Perfusion13, 192–204 (1988).
   Google Scholar
• Moen O, Høgåsen K, Fosse E et al. Attenuation of changes in leukocyte surface markers and complement activation with heparin-coated cardiopulmonary bypass. Ann. Thorac. Surg.63, 105–111 (1997).
   PubMed Web of Science ®Google Scholar
• Steinberg BM, Grossi EA, Schwartz DS et al. Heparin bonding of bypass circuits reduces cytokine release during cardiopulmonary bypass. Ann. Thorac. Surg.60(3), 525–529 (1995).
   PubMed Web of Science ®Google Scholar
• Barstad RM, Ovrum E, Ringdal M-AL et al. Induction of monocyte tissue factor procoagulant activity during coronary artery bypass surgery is reduced with heparin-coated extracorporeal circuit. Br. J. Haematol.94, 517–525 (1996).
   PubMedGoogle Scholar
• Khuri S, Valeri CR, Loscalzo J et al. Heparin causes platelet dysfunction and induces fibrinolysis before cardiopulmonary bypass. Ann. Thorac. Surg.60, 1008–1014 (1995).
   PubMed Web of Science ®Google Scholar
• Muriithi EW, Belcher PR, Day SP, Menys VC, Wheatley DJ. Heparin-induced platelet dysfunction and cardiopulmonary bypass. Ann. Thorac. Surg.69(6), 1827–1832 (2000).
   PubMed Web of Science ®Google Scholar
• Morel DR, Zapol WM, Thomas SJ et al. C5a and thromboxane generation associated with pulmonary vaso- and broncho-constriction during protamine reversal of heparin. Anesthesiology66(5), 597–604 (1987).
   PubMed Web of Science ®Google Scholar
• Wildevuur CR, Jansen PG, Bezemer PD et al. Clinical evaluation of Duraflo II heparin treated extracorporeal circulation circuits (2nd version). The European Working Group on heparin coated extracorporeal circulation circuits. Eur. J. Cardiothorac. Surg.11(4), 616–623 (1997).
   PubMed Web of Science ®Google Scholar
• Ranucci M, Mazzucco A, Pessotto R et al. Heparin-coated circuits for high-risk patients: a multicenter, prospective, randomized trial. Ann. Thorac. Surg.67, 994–1000 (1999).
   PubMed Web of Science ®Google Scholar
• Gorman RC, Ziats NP, Rao AK et al. Surface-bound heparin fails to reduce thrombin formation during clinical cardiopulmonary bypass. J. Thorac. Cardiovasc. Surg.111, 1–12 (1996).
   PubMed Web of Science ®Google Scholar
• Edmunds LH. Surface-bound heparin – panacea or peril? Ann. Thorac. Surg.58, 285–286 (1994).
   PubMedGoogle Scholar
• Baufreton C, Jansen PG, Le Besnerais P et al. Heparin coating with aprotinin reduces blood activation during coronary artery operations. Ann. Thorac. Surg.63(1), 50–56 (1997).
   PubMedGoogle Scholar
• Videm V, Mollnes TE, Fosse E et al. Heparin-coated cardiopulmonary bypass equipment. I. Biocompatibility markers and development of complications in a high-risk population. J. Thorac. Cardiovasc. Surg.117(4), 794–802 (1999).
   PubMed Web of Science ®Google Scholar
• Videm V, Mollnes TE, Bergh K et al. Heparin-coated cardiopulmonary bypass equipment. II. Mechanisms for reduced complement activation in vivo. J. Thorac. Cardiovasc. Surg.117(4), 803–809 (1999).
   PubMed Web of Science ®Google Scholar
• Pekna M, Hagman L, Halden E, Nilsson UR, Nilsson B, Thelin S. Complement activation during cardiopulmonary bypass: effects of immobilized heparin. Ann. Thorac. Surg.58, 421–424 (1994).
   PubMedGoogle Scholar
• de Vroege R, Huybregts R, van Oeveren W et al. The impact of heparin-coated circuits on hemodynamics during and after cardiopulmonary bypass. Artif. Organs29(6), 490–497 (2005).
   PubMed Web of Science ®Google Scholar
• Wendel HP, Weber N, Ziemer G. Increased adsorption of high molecular weight kininogen to heparin-coated artificial surfaces and correlation to hemocompatibility. Immunopharmacology43(2–3), 149–153 (1999).
   PubMed Web of Science ®Google Scholar
• Olson ST, Sheffer R, Francis AM. High molecular weight kininogen potentiates the heparin-accelerated inhibition of plasma kallikrein by antithrombin: role for antithrombin in the regulation of kallikrein. Biochemistry32(45), 12136–12147 (1993).
   PubMedGoogle Scholar
• te Velthuis H, Baufreton C, Jansen PGM et al. Heparin coating of extracorporeal circuits inhibits contact activation during cardiac operations. J. Thorac. Cardiovasc. Surg.114, 117–122 (1997).
   PubMed Web of Science ®Google Scholar
• Kazatchkine MD, Fearon DT, Silbert JE, Austen KF. Surface-associated heparin inhibits zymosan-induced activation of the human alternative complement pathway by augmenting the regulatory action of the control proteins on particle-bound C3b. J. Exp. Med.150(5), 1202–1215 (1979).
   PubMed Web of Science ®Google Scholar
• Mollnes TE, Riesenfeld J, Garred P et al. A new model for evaluation of biocompatibility: combined determination of neoepitopes in blood and on artificial surfaces demonstrates reduced complement activation by immobilization of heparin. Artif. Organs19(9), 909–917 (1995).
   PubMed Web of Science ®Google Scholar
• Deppisch R, Gohl H, Smeby L. Microdomain structure of polymeric surfaces – potential for improving blood treatment procedures. Nephrol. Dial. Transplant.13(6), 1354–1359 (1998).
   PubMed Web of Science ®Google Scholar
• Tsai C-C, Deppisch RM, Forrestal LJ et al. Surface modifying additives for improved device–blood compatibility. ASAIO J.40, M619–M624 (1994).
   Google Scholar
• Lovinger AJ, Han BJ, Padden FJ, Mirau PA. Morphology and properties of polycaprolactone-poly(dimethyl siloxane)-polycaprolactone triblock copolymers. J. Polymer Sci.31, 115–123 (1993).
   Google Scholar
• Okano T, Nishiyama S, Shinohara I et al. Effect of hydrophilic and hydrophobic microdomains on mode of interaction between block polymer and blood platelets. J. Biomed. Mater. Res.15(3), 393–402 (1981).
   PubMed Web of Science ®Google Scholar
• Okano T, Aoyagi T, Kataoka K et al. Hydrophilic–hydrophobic microdomain surfaces having an ability to suppress platelet aggregation and their in vitro anti-thrombogenicity. J. Biomed. Mater. Res.20, 919–927 (1986).
   PubMed Web of Science ®Google Scholar
• Defraigne JO, Pincemail J, Dekoster G et al. SMA circuits reduce platelet consumption and platelet factor release during cardiac surgery. Ann. Thorac. Surg.70(6), 2075–2081 (2000).
   PubMedGoogle Scholar
• Allen S, McBride WT, Young IS et al. A clinical, renal and immunological assessment of surface modifying additive treated (SMART) cardiopulmonary bypass circuits. Perfusion20(5), 255–262 (2005).
   Google Scholar
• Suhara H, Sawa Y, Nishimura M et al. Efficacy of a new coating material, PMEA, for cardiopulmonary bypass circuits in a porcine model. Ann. Thorac. Surg.71(5), 1603–1608 (2001).
   PubMed Web of Science ®Google Scholar
• Saito N, Motoyama S, Sawamoto J. Effects of new polymer-coated extracorporeal circuits on biocompatibility during cardiopulmonary bypass. Artif. Organs24(7), 547–554 (2000).
   PubMed Web of Science ®Google Scholar
• Ueyama K, Nishimura K, Nishina T, Nakamura T, Ikeda T, Komeda M. PMEA coating of pump circuit and oxygenator may attenuate the early systemic inflammatory response in cardiopulmonary bypass surgery. ASAIO J.50(4), 369–372 (2004).
   PubMed Web of Science ®Google Scholar
• Izuha H, Hattori M, Igari T, Wakamatsu D, Watanabe M, Yokoyama H. Changes in platelet aggregation during cardiopulmonary bypass: comparison of poly-2-methoxyethylacrylate and heparin as a circuit coating material. J. Artif. Organs8(1), 41–46 (2005).
   PubMedGoogle Scholar
• Gemmell CH, Ramirez SM, Yeo EL, Sefton MV. Platelet activation in whole blood by artificial surfaces: identification of platelet-derived microparticles and activated platelet binding to leukocytes as material-induced activation events. J. Lab. Clin. Med.125(2), 276–287 (1995).
   PubMed Web of Science ®Google Scholar
• Shimono T, Shomura Y, Tani K et al. Clinical evaluation of a silicone coated hollow fiber oxygenator. ASAIO J.43(5), M735–M739 (1997).
   Google Scholar
• Shimamoto A, Kanemitsu S, Fujinaga K et al. Biocompatibility of silicone-coated oxygenator in cardiopulmonary bypass. Ann. Thorac. Surg.69(1), 115–120 (2000).
   PubMed Web of Science ®Google Scholar
• Durrani AA, Hayward JA, Chapman D. Biomembranes as models for polymer surfaces. II. The syntheses of reactive species for covalent coupling of phosphorylcholine to polymer surfaces. Biomaterials7(2), 121–125 (1986).
   PubMed Web of Science ®Google Scholar
• Sugiyama K, Matsumoto T, Yamazaki Y. Evaluation of biocompatibility of the surface of polyethylene films modified with various water soluble polymers using Ar plasma-post polymerization technique. Macromol. Mater. Eng.282, 5–12 (2000).
   Google Scholar
• Murphy EF, Lu JR, Brewer J, Russell J, Penfold J. The reduced adsorption of proteins at the phosphoryl choline incorporated polymer–water interface. Langmuir15, 1313–1322 (1999).
   Web of Science ®Google Scholar
• Lewis AL, Tolhurst LA, Stratford PW. Analysis of a phosphorylcholine-based polymer coating on a coronary stent pre- and post-implantation. Biomaterials23, 1697–1706 (2002).
   PubMed Web of Science ®Google Scholar
• Lewis AL, Furze JD, Small S et al. Long-term stability of a coronary stent coating post-implantation. J. Biomed. Mater. Res.63(6), 699–705 (2002).
   PubMed Web of Science ®Google Scholar
• De Somer F, Francois K, van Oeveren W et al. Phosphorylcholine coating of extracorporeal circuits provides natural protection against blood activation by the material surface. Eur. J. Cardiothorac. Surg.18(5), 602–606 (2000).
   PubMedGoogle Scholar
• de Haan J, Boonstra PW, Monnink SHJ, Ebels T, van Oeveren W. Retransfusion of suctioned blood during cardiopulmonary bypass impairs hemostasis. Ann. Thorac. Surg.59, 901–907 (1995).
   PubMed Web of Science ®Google Scholar
• Chung JH, Gikakis N, Rao K, Drake TA, Colman RW, Edmunds LH. Pericardial blood activates the extrinsic coagulation pathway during clinical cardiopulmonary bypass. Circulation93, 2014–2018 (1996).
   PubMedGoogle Scholar
• De Somer F, Van Belleghem Y, Caes F et al. Tissue factor as the main activator of the coagulation system during cardiopulmonary bypass. J. Thorac. Cardiovasc. Surg.123(5), 951–958 (2002).
   PubMed Web of Science ®Google Scholar
• Tabuchi N, de Haan J, Boonstra PW, van Oeveren W. Activation of fibrinolysis in the pericardial cavity during cardiopulmonary bypass. J. Thorac. Cardiovasc. Surg.106, 828–833 (1993).
   PubMed Web of Science ®Google Scholar
• Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J. Clin. Invest.86, 385–391 (1990).
   PubMed Web of Science ®Google Scholar
• Ernofsson M, Thelin S, Siegbahn A. Monocyte tissue factor expression, cell activation, and thrombin formation during cardiopulmonary bypass: a clinical study. J. Thorac. Cardiovasc. Surg.113, 576–584 (1997).
   PubMed Web of Science ®Google Scholar
• Parratt R, Hunt BJ. Direct activation of factor X by monocytes occurs during cardiopulmonary bypass. Br. J. Haematol.101, 40–46 (1998).
   PubMedGoogle Scholar
• Hattori T, Khan MM, Colman RW, Edmunds LH Jr. Plasma tissue factor plus activated peripheral mononuclear cells activate factors VII and X in cardiac surgical wounds. J. Am. Coll. Cardiol.46(4), 707–713 (2005).
   Google Scholar
• Nollert G, Schwabenland I, Maktav D et al. Miniaturized cardiopulmonary bypass in coronary artery bypass surgery: marginal impact on inflammation and coagulation but loss of safety margins. Ann. Thorac. Surg.80(6), 2326–2332 (2005).
   PubMed Web of Science ®Google Scholar
• Mack MJ, Brown PP, Kugelmass AD et al. Current status and outcomes of coronary revascularization 1999 to 2002: 148,396 surgical and percutaneous procedures. Ann. Thorac. Surg.77(3), 761–766 (2004).
   PubMed Web of Science ®Google Scholar